The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte ...

Let us delve into some of the TLR agonists in the clinic and why the careful selection of these drugs is crucial.

Results published in the peer-reviewed journal Investigational New DrugsStudy in heavily pre-treated patients with solid tumor indications who had progressed on prior immune ...

IO Biotech's first-in-class vaccine performs double duty, killing cancer cells and enhancing the tumor microenvironment. A ...

Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes (TILs) may be ...

This review explores the role of PET in imaging immune activation, particularly in oncology. 18F-FDG is widely used for assessing treatment response to immunotherapies and can demonstrate unique ...

Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional bispecific molecules – driving both ...

Patients with advanced non-small cell lung cancer (NSCLC) are often treated with immunotherapy drugs known as checkpoint inhibitors, which are designed to strengthen the immune system's ability to ...

Highlights include work focused on AI, precision medicine, immunotherapies and more LOS ANGELES--(BUSINESS WIRE)--Researchers ...

Preclinical in vitro and in vivo data show enhanced anti-tumor activity when combining visugromab, a GDF-15-neutralizing antibody candidate, with approved antibody-drug-conjugate (ADC) treatment ...